Dietary salt restriction improves cardiac and adipose tissue pathology independently of obesity in a rat model of metabolic syndrome

Journal of the American Heart Association

Volumn 3, Issue 6, 2014, Pages

  Hattori, Takuya ^a   Murase, Tamayo ^a   Takatsu, Miwa ^a   Nagasawa, Kai ^a   Matsuura, Natsumi ^a   Watanabe, Shogo ^a   Murohara, Toyoaki ^a   Nagata, Kohzo ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Diet; Hypertension; Obesity; Remodeling; Sodium

Indexed keywords

GLUCOSE; AUTACOID; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; INSULIN; SALT INTAKE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDITIS; CONTROLLED STUDY; DAHL SALT RESISTANT RAT; DIASTOLIC DYSFUNCTION; DOWN REGULATION; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HEART FUNCTION; HEART HEMODYNAMICS; HEART HYPERTROPHY; HEART INJURY; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HYPERTENSION; INSULIN BLOOD LEVEL; INTRAABDOMINAL FAT; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; SODIUM RESTRICTION; ZUCKER RAT; AGE; ANIMAL; BLOOD; CARDIOMEGALY; DAHL RAT; DIET THERAPY; DISEASE MODEL; FIBROSIS; GENETICS; HEART MUSCLE; HEMODYNAMICS; INSULIN RESISTANCE; METABOLISM; PATHOLOGY; SALT INTAKE; TIME;

AGE FACTORS; ANIMALS; BIOMARKERS; BLOOD GLUCOSE; CARDIOMEGALY; DIET, SODIUM-RESTRICTED; DISEASE MODELS, ANIMAL; FIBROSIS; HEMODYNAMICS; HYPERTENSION; INFLAMMATION MEDIATORS; INSULIN; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; MALE; METABOLIC SYNDROME X; MYOCARDIUM; OBESITY; OXIDATIVE STRESS; RATS, INBRED DAHL; RATS, ZUCKER; RENIN-ANGIOTENSIN SYSTEM; SODIUM CHLORIDE, DIETARY; TIME FACTORS;

EID: 84924786246     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.114.001312     Document Type: Article

References (44)

1. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433-438.
2. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-2716.
3. Matsuzawa Y. Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2006;3:35-42.
4. Cuspidi C, Meani S, Fusi V, Severgnini B, Valerio C, Catini E, Leonetti G, Magrini F, Zanchetti A. Metabolic syndrome and target organ damage in untreated essential hypertensives. J Hypertens. 2004;22:1991-1998.
5. He FJ, MacGregor GA. A comprehensive review on salt and health and current experience of worldwide salt reduction programmes. J Hum Hypertens. 2009;23:363-384.
6. Chen J, Gu D, Huang J, Rao DC, Jaquish CE, Hixson JE, Chen CS, Chen J, Lu F, Hu D, Rice T, Kelly TN, Hamm LL, Whelton PK, He J. Metabolic syndrome and salt sensitivity of blood pressure in non-diabetic people in China: a dietary intervention study. Lancet. 2009;373:829-835.
7. Rocchini AP, Key J, Bondie D, Chico R, Moorehead C, Katch V, Martin M. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med. 1989;321:580-585.
8. Ogihara T, Asano T, Ando K, Sakoda H, Anai M, Shojima N, Ono H, Onishi Y, Fujishiro M, Abe M, Fukushima Y, Kikuchi M, Fujita T. High-salt diet enhances insulin signaling and induces insulin resistance in Dahl salt-sensitive rats. Hypertension. 2002;40:83-89.
9. Dyer AR, Elliott P, Shipley M, Stamler R, Stamler J. Body mass index and associations of sodium and potassium with blood pressure in INTERSALT. Hypertension. 1994;23:729-736.
10. INTERSALT Cooperative Research Group. INTERSALT: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. BMJ. 1988;297:319-328.
11. Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ishimitsu T, Ito M, Ito S, Itoh H, Iwao H, Kai H, Kario K, Kashihara N, Kawano Y, Kim-Mitsuyama S, Kimura G, Kohara K, Komuro I, Kumagai H, Matsuura H, Miura K, Morishita R, Naruse M, Node K, Ohya Y, Rakugi H, Saito I, Saitoh S, Shimada K, Shimosawa T, Suzuki H, Tamura K, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Umemura S. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2014). Hypertens Res. 2014;37:253-387.
12. Stolarz-Skrzypek K, Kuznetsova T, Thijs L, Tikhonoff V, Seidlerova J, Richart T, Jin Y, Olszanecka A, Malyutina S, Casiglia E, Filipovsky J, Kawecka-Jaszcz K, Nikitin Y, Staessen JA. Fatal and nonfatal outcomes, incidence of hypertension, and blood pressure changes in relation to urinary sodium excretion. JAMA. 2011;305:1777-1785.
13. Alderman MH, Cohen H, Madhavan S. Dietary sodium intake and mortality: the National Health and Nutrition Examination Survey (NHANES I). Lancet. 1998;351:781-785.
14. Cohen HW, Hailpern SM, Fang J, Alderman MH. Sodium intake and mortality in the NHANES II follow-up study. Am J Med. 2006;119:275.e277-214.
15. fa rat. Nutr Diabetes. 2011;1: e1.
16. fa rats as a new animal model of metabolic syndrome. Hypertension. 2012;59:694-704.
17. Reffelmann T, Kloner RA. Transthoracic echocardiography in rats. Evaluation of commonly used indices of left ventricular dimensions, contractile performance, and hypertrophy in a genetic model of hypertrophic heart failure (SHHF-Mcc-facp-Rats) in comparison with Wistar rats during aging. Basic Res Cardiol. 2003;98:275-284.
18. Nagata K, Iwase M, Sobue T, Yokota M. Differential effects of dobutamine and a phosphodiesterase inhibitor on early diastolic filling in patients with congestive heart failure. J Am Coll Cardiol. 1995;25:295-304.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
20. Miyachi M, Yazawa H, Furukawa M, Tsuboi K, Ohtake M, Nishizawa T, Hashimoto K, Yokoi T, Kojima T, Murate T, Yokota M, Murohara T, Koike Y, Nagata K. Exercise training alters left ventricular geometry and attenuates heart failure in Dahl salt-sensitive hypertensive rats. Hypertension. 2009;53:701-707.
21. Ichihara S, Noda A, Nagata K, Obata K, Xu J, Ichihara G, Oikawa S, Kawanishi S, Yamada Y, Yokota M. Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure. Cardiovasc Res. 2006;69:726-735.
22. Somura F, Izawa H, Iwase M, Takeichi Y, Ishiki R, Nishizawa T, Noda A, Nagata K, Yamada Y, Yokota M. Reduced myocardial sarcoplasmic reticulum Ca(2+)-ATPase mRNA expression and biphasic force-frequency relations in patients with hypertrophic cardiomyopathy. Circulation. 2001;104:658-663.
23. Nagata K, Somura F, Obata K, Odashima M, Izawa H, Ichihara S, Nagasaka T, Iwase M, Yamada Y, Nakashima N, Yokota M. AT1 receptor blockade reduces cardiac calcineurin activity in hypertensive rats. Hypertension. 2002;40:168-174.
24. Sakata Y, Yamamoto K, Mano T, Nishikawa N, Yoshida J, Hori M, Miwa T, Masuyama T. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of angiotensin-converting enzyme inhibitor. Circulation. 2004;109:2143-2149.
25. Hattori T, Murase T, Sugiura Y, Nagasawa K, Takahashi K, Ohtake M, Miyachi M, Murohara T, Nagata K. Effects of salt status and blockade of mineralocorticoid receptors on aldosterone-induced cardiac injury. Hypertens Res. 2014;37:125-133.
26. Takatsu M, Nakashima C, Takahashi K, Murase T, Hattori T, Ito H, Murohara T, Nagata K. Calorie restriction attenuates cardiac remodeling and diastolic dysfunction in a rat model of metabolic syndrome. Hypertension. 2013;62:957-965.
27. fa rats: a new animal model of metabolic syndrome. Hypertens Res. 2012;35:186-193.
28. Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata H, Kato T, Izawa H, Murohara T, Yokota M. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension. 2006;47:656-664.
29. Cook NR, Cutler JA, Obarzanek E, Buring JE, Rexrode KM, Kumanyika SK, Appel LJ, Whelton PK. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ. 2007;334:885-888.
30. Weber KT. From inflammation to fibrosis: a stiff stretch of highway. Hypertension. 2004;43:716-719.
31. Bradham WS, Bozkurt B, Gunasinghe H, Mann D, Spinale FG. Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective. Cardiovasc Res. 2002;53:822-830.
32. Melendez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension. 2010;56:225-231.
33. Matsui H, Ando K, Kawarazaki H, Nagae A, Fujita M, Shimosawa T, Nagase M, Fujita T. Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder. Hypertension. 2008;52:287-294.
34. Schmid C, Castrop H, Reitbauer J, Della Bruna R, Kurtz A. Dietary salt intake modulates angiotensin II type 1 receptor gene expression. Hypertension. 1997;29:923-929.
35. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999;19:972-978.
36. Baudrand R, Lian CG, Lian BQ, Ricchiuti V, Yao TM, Li J, Williams GH, Adler GK. Long-term dietary sodium restriction increases adiponectin expression and ameliorates the proinflammatory adipokine profile in obesity. Nutr Nutr Metab Cardiovasc Dis. 2014;24:34-41.
37. Kamei N, Tobe K, Suzuki R, Ohsugi M, Watanabe T, Kubota N, Ohtsuka-Kowatari N, Kumagai K, Sakamoto K, Kobayashi M, Yamauchi T, Ueki K, Oishi Y, Nishimura S, Manabe I, Hashimoto H, Ohnishi Y, Ogata H, Tokuyama K, Tsunoda M, Ide T, Murakami K, Nagai R, Kadowaki T. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem. 2006;281:26602-26614.
38. ser307 phosphorylation in rat tissues. J Endocrinol. 2005;185:429-437.
39. Prada P, Okamoto MM, Furukawa LN, Machado UF, Heimann JC, Dolnikoff MS. High-or low-salt diet from weaning to adulthood: effect on insulin sensitivity in Wistar rats. Hypertension. 2000;35:424-429.
40. Catanozi S, Rocha JC, Nakandakare ER, Passarelli M, Mesquita CH, Silva AA, Dolnikoff MS, Harada LM, Quintao EC, Heimann JC. The rise of the plasma lipid concentration elicited by dietary sodium chloride restriction in Wistar rats is due to an impairment of the plasma triacylglycerol removal rate. Atherosclerosis. 2001;158:81-86.
41. Townsend RR, Kapoor S, McFadden CB. Salt intake and insulin sensitivity in healthy human volunteers. Clin Sci (Lond). 2007;113:141-148.
42. Haruta T, Uno T, Kawahara J, Takano A, Egawa K, Sharma PM, Olefsky JM, Kobayashi M. A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol. 2000;14:783-794.
43. Ueno M, Carvalheira JB, Tambascia RC, Bezerra RM, Amaral ME, Carneiro EM, Folli F, Franchini KG, Saad MJ. Regulation of insulin signalling by hyperinsulinaemia: role of IRS-1/2 serine phosphorylation and the mTOR/p70 S6K pathway. Diabetologia. 2005;48:506-518.
44. Fujita T. Mineralocorticoid receptors, salt-sensitive hypertension, and metabolic syndrome. Hypertension. 2010;55:813-818.